Retatrutide (LY3437943) | CAS 2381089-83-2 | Triple GIP/GLP-1/Glucagon Receptor Agonist | Knowlux

Product Description

Retatrutide, CAS 2381089-83-2, is a synthetic triple receptor agonist supplied by Knowlux for research and development use. It is a 39-amino-acid peptide incorporating non-natural amino acid substitutions (Aib, α-methyl-leucine) for DPP-IV resistance, and a C20 fatty diacid side chain that enables albumin binding and a prolonged half-life. The molecular formula is C221H342N46O68 and the molecular weight is 4731.33 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Product Parameters

Product Details

1. Overview

Retatrutide (LY3437943) is an investigational triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is being developed by Eli Lilly for obesity, type 2 diabetes, and related metabolic conditions, and is not approved in any country. Phase 2 clinical data report a mean body weight reduction of up to 24.2% at 48 weeks, the highest reported among incretin-based therapies to date . The molecule incorporates a C20 fatty diacid side chain that enables albumin binding, supporting once-weekly subcutaneous administration.

2. Mechanism of Action

Retatrutide activates GIPR, GLP-1R, and GCGR. Functional assay data report EC50 values of 0.0643 nM (GIPR), 0.775 nM (GLP-1R), and 5.79 nM (GCGR) for the human receptors, indicating preferential activity at GIPR relative to GLP-1R and GCGR . The glucagon receptor activity is thought to contribute to increased energy expenditure and fat oxidation, distinguishing it from dual GIP/GLP-1 agonists. Preclinical and clinical data suggest the compound reduces food intake, improves lipid metabolism and glucose homeostasis, and enhances energy expenditure.

3. Quality Control

Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.

4. Applications

• Reference standard and impurity studies for triple incretin receptor agonist analytical methods

• GIPR, GLP-1R and GCGR binding and functional assay development

• Formulation development for long-acting injectable peptides

• Metabolic disease model research, including obesity and glucose homeostasis studies

• LC-MS, immunoassay and bioassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for ?20 °C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, GMO/allergen-free statement, residual solvent statement. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for pharmaceutical research and development use by licensed organisations only. It is not for direct human or veterinary administration, not for retail sale, and not for personal use. Retatrutide is an investigational molecule and is not approved for any therapeutic indication in any country. Mechanism and clinical development statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.